Press release March 26: Farmacia Nordic AB takes over rights and distribution of the well-known ear product Vaxol® by acquiring Vaxol Ltd.
26 mars 2024
STOCKHOLM, March 26: Farmacia Nordic AB today announces the acquisition of Vaxol Ltd, owner of the prominent Vaxol® brand. The product is well known in ear care and has established itself in over 20 markets, in several of them as market leader. In connection with the acquisition, Farmacia Nordic AB takes over the rights to sell Vaxol globally and takes immediate control over the distribution of the product throughout Scandinavia.
The acquisition strengthens Farmacia Nordic AB’s position as a leading player in ear care by solidifying their role as a trusted partner in earwax treatment. It also provides the company with an opportunity to expand its global presence and offer the product to even more customers around the world.
“We are very pleased to welcome Vaxol Ltd and their product Vaxol® to the Farmacia Nordic AB family. We will invest heavily in Vaxol® to further strengthen its position in the market,” says Johan Bloom, CEO of Farmacia Nordic AB.
With the acquisition of Vaxol Ltd, Farmacia Nordic AB looks forward to continuing its commitment to delivering high-quality products to its customers.
For more information about Farmacia Nordic AB and their acquisition of Vaxol Ltd, please contact: Johan Bloom, CEO, Farmacia Nordic AB, info@farmacianordic.com, +46 733 64 84 90
About Farmacia Nordic
Farmacia Nordic AB is a new player in the pharmaceutical industry, focusing on offering innovative solutions in pharmaceuticals and medical technology. With a rapidly growing product portfolio, Farmacia Nordic AB strives to improve people’s quality of life by providing high-quality medicines and treatment options.
Share on social media